1. Home
  2. CB vs TGTX Comparison

CB vs TGTX Comparison

Compare CB & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chubb Limited

CB

Chubb Limited

HOLD

Current Price

$341.54

Market Cap

129.9B

Sector

Finance

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$57.19

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CB
TGTX
Founded
1985
1993
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
129.9B
8.5B
IPO Year
1995
2008

Fundamental Metrics

Financial Performance
Metric
CB
TGTX
Price
$341.54
$57.19
Analyst Decision
Buy
Strong Buy
Analyst Count
21
5
Target Price
$332.76
$49.80
AVG Volume (30 Days)
1.4M
1.8M
Earning Date
04-21-2026
05-04-2026
Dividend Yield
1.19%
N/A
EPS Growth
13.13
1746.67
EPS
5.88
0.17
Revenue
$59,402,000,000.00
$2,785,000.00
Revenue This Year
N/A
$49.08
Revenue Next Year
$5.31
$26.69
P/E Ratio
$58.15
$332.18
Revenue Growth
6.54
N/A
52 Week Low
$265.30
$26.76
52 Week High
$365.91
$59.30

Technical Indicators

Market Signals
Indicator
CB
TGTX
Relative Strength Index (RSI) 48.48 60.38
Support Level $334.77 $51.51
Resistance Level $347.25 $58.12
Average True Range (ATR) 4.80 2.26
MACD 0.42 0.06
Stochastic Oscillator 49.75 81.68

Price Performance

Historical Comparison
CB
TGTX

About CB Chubb Limited

ACE acquired Chubb in 2016 and assumed the Chubb name. The combination made the new Chubb one of the largest domestic property and casualty insurers, with operations in over 50 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: